MedPath
HSA Approval

ACTIHIST SYRUP

SIN10474P

ACTIHIST SYRUP

ACTIHIST SYRUP

November 30, 1998

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R01BA52

pseudoephedrine, combinations

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

HOVID BHD

Active Ingredients

PSEUDOEPHEDRINE HCl

30 mg/5 ml

Pseudoephedrine

TRIPROLIDINE HCl

1.25 mg/5 ml

Triprolidine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ACTIHIST SYRUP - HSA Approval | MedPath